These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30060445)

  • 1. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.
    Fakiruddin KS; Ghazalli N; Lim MN; Zakaria Z; Abdullah S
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
    Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
    Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.
    Cafforio P; Viggiano L; Mannavola F; Pellè E; Caporusso C; Maiorano E; Felici C; Silvestris F
    Stem Cell Res Ther; 2017 Sep; 8(1):206. PubMed ID: 28962646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
    Moniri MR; Sun XY; Rayat J; Dai D; Ao Z; He Z; Verchere CB; Dai LJ; Warnock GL
    Cancer Gene Ther; 2012 Sep; 19(9):652-8. PubMed ID: 22767216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered human mesenchymal stem cells for neuroblastoma therapeutics.
    Nieddu V; Piredda R; Bexell D; Barton J; Anderson J; Sebire N; Kolluri K; Janes SM; Karteris E; Sala A
    Oncol Rep; 2019 Jul; 42(1):35-42. PubMed ID: 31115546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.
    Lee HJ; Yang HM; Choi YS; Park SH; Moon SH; Lee YS; Sung YC; Kim SJ
    Ann Surg; 2013 May; 257(5):952-60. PubMed ID: 23108118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A TRAIL-Delivered Lipoprotein-Bioinspired Nanovector Engineering Stem Cell-Based Platform for Inhibition of Lung Metastasis of Melanoma.
    Chen K; Cao X; Li M; Su Y; Li H; Xie M; Zhang Z; Gao H; Xu X; Han Y; Zhou J; Wang W
    Theranostics; 2019; 9(10):2984-2998. PubMed ID: 31244937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma.
    Choi SA; Hwang SK; Wang KC; Cho BK; Phi JH; Lee JY; Jung HW; Lee DH; Kim SK
    Neuro Oncol; 2011 Jan; 13(1):61-9. PubMed ID: 21062796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
    Tang XJ; Lu JT; Tu HJ; Huang KM; Fu R; Cao G; Huang M; Cheng LH; Dai LJ; Zhang L
    Anticancer Res; 2014 Feb; 34(2):729-34. PubMed ID: 24511006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK.
    Kim SW; Kim SJ; Park SH; Yang HG; Kang MC; Choi YW; Kim SM; Jeun SS; Sung YC
    Clin Cancer Res; 2013 Jan; 19(2):415-27. PubMed ID: 23204131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells.
    Xia P; Wang W; Bai Y
    Apoptosis; 2014 Mar; 19(3):491-505. PubMed ID: 24242915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
    Luetzkendorf J; Mueller LP; Mueller T; Caysa H; Nerger K; Schmoll HJ
    J Cell Mol Med; 2010 Sep; 14(9):2292-304. PubMed ID: 19508388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
    Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
    J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
    Ciavarella S; Grisendi G; Dominici M; Tucci M; Brunetti O; Dammacco F; Silvestris F
    Br J Haematol; 2012 Jun; 157(5):586-98. PubMed ID: 22420897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells.
    Guo XR; Yang ZS; Tang XJ; Zou DD; Gui H; Wang XL; Ma SN; Yuan YH; Fang J; Wang B; Zhang L; Sun XY; Warnock GL; Dai LJ; Tu HJ
    Oncotarget; 2016 Aug; 7(34):55529-55542. PubMed ID: 27487125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-Specific Integration of TRAIL in iPSC-Derived Mesenchymal Stem Cells for Targeted Cancer Therapy.
    Wang Z; Chen H; Wang P; Zhou M; Li G; Hu Z; Hu Q; Zhao J; Liu X; Wu L; Liang D
    Stem Cells Transl Med; 2022 Mar; 11(3):297-309. PubMed ID: 35267023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
    Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
    Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model.
    Shamili FH; Bayegi HR; Salmasi Z; Sadri K; Mahmoudi M; Kalantari M; Ramezani M; Abnous K
    Int J Pharm; 2018 Oct; 549(1-2):218-229. PubMed ID: 30075248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.